Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis

doi:10.12998/wjcc.v10.i19.6360

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3416)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

187

WORD

HTML

1541

Figures (1-5)

452

Sum=2239

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

203

Download

339

Sum=542

Publishing Process of This Article

Item

Count

Browse

240

Download

395

Sum=635

Jul 6, 2022 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jul 6, 2022; 10(19): 6360-6369
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6360

Full Size Figure Download Figure

Figure 2 Pharmacokinetics of gefitinib in patients undergoing hemodialysis and those with normal renal function. A: The C_max of gefitinib in patients undergoing HD was similar to subjects with NRF; B: One patient showed the C_trough of gefitinib was 410 ng/mL. The two patients undergoing HD showed the C_trough of gefitinib was 102-386 ng/mL; C: The plasma concentration of gefitinib were similar in patients before and after HD. C_max: Maxium concentration; C_trough: Trough concentration; HD: Hemodialysis; NRF: Normal renal function.

Citation: Lan CC, Hsieh PC, Huang CY, Yang MC, Su WL, Wu CW, Wu YK. Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. World J Clin Cases 2022; 10(19): 6360-6369
URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6360.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6360